Insulin-like growth factor binding proteins-3 and -5: Central mediators of fibrosis and promising new therapeutic targets

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 140-145

  Veraldi, Kristen L ^a   Feghali Bostwick, Carol A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix; Fibrosis; Idiopathic pulmonary fibrosis; IGFBP; Senescence; Systemic sclerosis

Indexed keywords

ANTIFIBROTIC AGENT; KARYOPHERIN; MESSENGER RNA; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

AIRWAY REMODELING; CELL ACTIVATION; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; HUMAN; INTESTINAL FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SENESCENCE; SKIN FIBROSIS; UPREGULATION;

EID: 84863949759     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010140     Document Type: Review

References (78)

1. Bach LA, Headey SJ, Norton RS. IGF-binding proteins--the pieces are falling into place. Trends Endocrinol Metab 2005; 16(5): 228-34.
2. Rosenfeld RG, Hwa V, Wilson E, Plymate SR, Oh Y. The insulinlike growth factor-binding protein superfamily. Growth Horm IGF Res 2000; 10 (Suppl A): S16-7.
3. Gourmelen M, Perin L, Le Bouc Y. IGFs and their binding proteins. Nucl Med Biol 1994; 21(3): 297-302.
4. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000; 278(6): E967-76.
5. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factorbinding protein (IGFBP) superfamily. Endocr Rev 1999; 20(6): 761-87.
6. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140(1-2): 19-24.
7. Holly JM, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999; 162(3): 321-30.
8. Murphy LJ. Insulin-like growth factor-binding proteins: functional diversity or redundancy? J Mol Endocrinol 1998; 21(2): 97-107.
9. Scharf J, Ramadori G, Braulke T, Hartmann H. Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology 1996; 23(4): 818-27.
10. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54(3): 145-8.
11. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and-5 is mediated by the importin beta subunit. J Biol Chem 2000; 275(31): 23462-70.
12. Iosef C, Gkourasas T, Jia CY, Li SS, Han VK. A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. Endocrinology 2008; 149(3): 1214-26.
13. Iosef C, Vilk G, Gkourasas T, et al. Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. Cell Signal 2010; 22(7): 1033-43.
14. Sureshbabu A, Tonner E, Allan GJ, Flint DJ. Relative Roles of TGF-and IGFBP-5 in Idiopathic Pulmonary Fibrosis. Pulm Med 2011; 2011: 517687.
15. Ruan W, Ying K. Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis? Pathol Res Pract 2010; 206(8): 537-43.
16. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18(7): 816-27.
17. Murray JC. Keloids and hypertrophic scars. Clin Dermatol 1994; 12(1): 27-37.
18. Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2008; 128(5): 1298-310.
19. Satish L, Lyons WJ, Hebda PA, Wells A. Gene expression patterns in isolated keloid fibroblasts. Wound Repair Regen 2006; 14(4): 463-70.
20. Chen W, Fu X, Sun X, Sun T, Zhao Z, Sheng Z. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res 2003; 113(2): 208-16.
21. Seifert O, Bayat A, Geffers R, et al. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 2008; 16(2): 254-65.
22. Russell SB, Russell JD, Trupin KM, et al. Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 2010; 130(10): 2489-96.
23. Phan TT, Lim IJ, Bay BH, et al. Role of IGF system of mitogens in the induction of fibroblast proliferation by keloid-derived keratinocytes in vitro. Am J Physiol Cell Physiol 2003; 284(4): C860-9.
24. Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999; 42(7): 1451-7.
25. Yasuoka H, Larregina AT, Yamaguchi Y, Feghali BCA. Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2008; 2: 17-22.
26. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali BCA. Insulinlike growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166(2): 399-407.
27. Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AMK, Feghali BCA. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006; 169(5): 1633-42.
28. Veraldi KL, Gibson BT, Yasuoka H, et al. Role of insulin-like growth factor binding protein-3 in allergic airway remodeling. Am J Respir Crit Care Med 2009; 180(7): 611-7.
29. Cohen P, Rajah R, Rosenbloom J, Herrick DJ. IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 278(3): L545-51.
30. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160(2): 736-55.
31. Allen JT, Bloor CA, Knight RA, Spiteri MA. Expression of insulinlike growth factor binding proteins in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1998; 19(2): 250-8.
32. Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL, Rom WN. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151(5): 1597-603.
33. Yasuoka H, Yamaguchi Y, Feghali BCA. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol 2009; 41(2): 179-88.
34. Hsu E, Shi H, Jordan RM, Lyons WJ, Pilewski JM, Feghali BCA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63(3): 783-94.
35. Brissett M, Veraldi K, Pilewski J, Medsger T, Feghali-Bostwick C. Localized expression of tenascin in systemic sclerosis-associated lung fibrosis and its regulation by IGF binding protein (IGFBP)-3. Arthritis Rheum 2012; 64: 272-80.
36. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998; 27(3): 563-94.
37. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126(6): 1504-17.
38. Zeeh JM, Hoffmann P, Sottili M, Eysselein VE, McRoberts JA. Up-regulation of insulinlike growth factor I binding sites in experimental colitis in rats. Gastroenterology 1995; 108(3): 644-52.
39. Zimmermann EM, Li L, Hou YT, Cannon M, Christman GM, Bitar KN. IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am J Physiol 1997; 273(4 Pt 1): G875-82.
40. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, Lund PK. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol Gastrointest Liver Physiol 2000; 278(3): G447-57.
41. Flynn RS, Mahavadi S, Murthy KS, et al. Endogenous IGFBP-3 regulates excess collagen expression in intestinal smooth muscle cells of Crohn's disease strictures. Inflamm Bowel Dis 2011; 17(1): 193-201.
42. Boers W, Aarrass S, Linthorst C, Pinzani M, Elferink RO, Bosma P. Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem 2006; 281(24): 16289-95.
43. Sokolovi A, Sokolovi M, Boers W, Elferink RP, Bosma PJ. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 2010; 3: 3.
44. Sappino AP, Schürch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990; 63(2): 144-61.
45. Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003; 29(3 Pt 1): 397-404.
46. Yasuoka H, Hsu E, Ruiz XD, Steinman RA, Choi AM, Feghali BCA. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and-independent mechanisms. Am J Pathol 2009; 175(2): 605-15.
47. Sureshbabu A, Okajima H, Yamanaka D, et al. IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochem Soc Trans 2009; 37(Pt 4): 882-5.
48. Massagué J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103(2): 295-309.
49. Abrass CK, Hansen KM. Insulin-like growth factor-binding protein-5-induced laminin gamma1 transcription requires filamin A. J Biol Chem 2010; 285(17): 12925-34.
50. Allan GJ, Beattie J, Flint DJ. Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol 2008; 199(2): 155-64.
51. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3(4): 364-72.
52. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161(2 Pt 1): 646-64.
53. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174(7): 810-6.
54. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105(35): 13051-6.
55. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178(7): 729-37.
56. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356(13): 1317-26.
57. Garcia CK, Wright WE, Shay JW. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res 2007; 35(22): 7406-16.
58. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 2011; 8(2): 158-62.
59. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155(1): 242-8.
60. Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 2006; 35(6): 681-8.
61. Nyunoya T, Monick MM, Klingelhutz AL, et al. Cigarette smoke induces cellular senescence via Werner's syndrome protein downregulation. Am J Respir Crit Care Med 2009; 179(4): 279-87.
62. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63(11): 2705-15.
63. Kuilman T, Peeper DS. Senescence-messaging secretome: SMSing cellular stress. Nat Rev Cancer 2009; 9(2): 81-94.
64. Suzuki T, Minagawa S, Michishita E, et al. Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp Gerontol 2001; 36(3): 465-74.
65. Dokmanovic M, Chang BD, Fang J, Roninson IB. Retinoidinduced growth arrest of breast carcinoma cells involves coactivation of multiple growth-inhibitory genes. Cancer Biol Ther 2002; 1(1): 24-7.
66. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA 2002; 99(1): 389-94.
67. Yoon IK, Kim HK, Kim YK, et al. Exploration of replicative senescence-associated genes in human dermal fibroblasts by cDNA microarray technology. Exp Gerontol 2004; 39(9): 1369-78.
68. Hampel B, Fortschegger K, Ressler S, et al. Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence. Exp Gerontol 2006; 41(5): 474-81.
69. Moerman EJ, Thweatt R, Moerman AM, Jones RA, Goldstein S. Insulin-like growth factor binding protein-3 is overexpressed in senescent and quiescent human fibroblasts. Exp Gerontol 1993; 28(4-5): 361-70.
70. Goldstein S, Moerman EJ, Baxter RC. Accumulation of insulin-like growth factor binding protein-3 in conditioned medium of human fibroblasts increases with chronologic age of donor and senescence in vitro. J Cell Physiol 1993; 156(2): 294-302.
71. Kim KS, Seu YB, Baek SH, et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007; 18(11): 4543-52.
72. Kim KS, Kim MS, Seu YB, Chung HY, Kim JH, Kim JR. Regulation of replicative senescence by insulin-like growth factorbinding protein 3 in human umbilical vein endothelial cells. Aging Cell 2007; 6(4): 535-45.
73. Varga J, Pasche B. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 2008; 20(6): 720-8.
74. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303(5659): 848-51.
75. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56(7): 1545-50.
76. Martin JL, Ballesteros M, Baxter RC. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 1992; 131(4): 1703-10.
77. Oh Y, Müller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270(23): 13589-92.
78. Kuemmerle JF, Murthy KS, Bowers JG. IGFBP-3 activates TGFbeta receptors and directly inhibits growth in human intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2004; 287(4): G795-802.